What changed from existing technology?
This study found that CLPTM1L, a protein linked to cancer resistance, may help predict cancer outcomes and immune responses in many cancer types, especially breast cancer.
This is the first comprehensive analysis of CLPTM1L's role across multiple cancer types, including its immune-related functions and potential as a prognostic biomarker.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
cance, regulatory mechanisms, and immunological roles remains lacking. This study aimed to systematically characterize CLPTM1L across human cancers and v
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
- 장기·실사용 검증 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Validation stage
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
CLPTM1L may serve as a potential biomarker for cancer prognosis and immune response prediction, particularly in breast cancer, but further validation is needed for clinical application.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.